<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A retrospective review of patients treated for endemic Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in Ghana was undertaken to evaluate the efficacy of intrathecal (IT) chemoprophylaxis in preventing central <z:mp ids='MP_0008912'>nervous</z:mp> system (<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>) relapse </plain></SENT>
<SENT sid="1" pm="."><plain>Patients treated before 1974 received no IT chemoprophylaxis and those treated between 1974 and 1979 received IT <z:chebi fb="0" ids="44185">methotrexate</z:chebi> in addition to systemic chemotherapy </plain></SENT>
<SENT sid="2" pm="."><plain>In patients presenting with facial disease only (Stages I-II), there was no significant difference in the frequency of <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> relapse between those receiving IT chemoprophylaxis and those not receiving any </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> relapse was, however, significantly reduced in patients presenting with abdominal disease (Stage III) who received IT chemoprophylaxis in addition to systemic combination therapy </plain></SENT>
<SENT sid="4" pm="."><plain>This was associated with an improved survival </plain></SENT>
</text></document>